GRIA3
Glutamate receptor 3
As of the edition of 20 October 2026, GRIA3 (glutamate receptor 3, UniProt P42263) has 13 drugs tested at it and 17 companies on the list, 7 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P42263
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Disease areas
- Nervous system; Mental health; Nutrition and metabolism; Chemically induced; Heart and blood vessels; Hormones; Inherited and neonatal; Cancer
- Registered trials of its drugs
- 357
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Went quiet | 6 |
| Stopped | 3 |
| Total | 13 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Topiramate | Marketed | Phase 4 | none listed |
| Perampanel | Marketed | Phase 4 | Ended 2026 |
| Pesampator | Stopped | Phase 2 | none listed |
| Osavampator | Active | Phase 3 | none listed |
| Selurampanel | Stopped | Phase 2 | none listed |
| Farampator | Stopped | Phase 2 | none listed |
| Irampanel | Went quiet | Phase 1 | none listed |
| MK-8777 | Went quiet | Phase 2 | none listed |
| Mibampator | Went quiet | Phase 2 | none listed |
| Tezampanel anhydrous | Active | Phase 2 | none listed |
| Zonampanel | Went quiet | Phase 2 | none listed |
| CX1739 | Went quiet | Phase 2 | none listed |
12 of 13 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Route B | 2 |
| Engaged | 7 |
| Undetermined | 1 |
| Total on the list | 17 |
| Company | Route |
|---|---|
| Eisai | Route B |
| Merck & Co. | Route A |
| Biogen | Route A |
The other 14 companies at GRIA3
In the product17 companies in all; 14 are not named here, and no score is.
See the 17 companies at GRIA3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.